Sanofi Showcases Innovative Diabetes Therapies and Digital Management Solutions at the 4th China International Import Expo

SHANGHAI, Nov. 8, 2021 /PRNewswire/ -- As a company with nearly a century of experience in diabetes management, Sanofi continues to innovate and invest in the diabetes field, consistently delivering innovative treatment solutions to patients with diabetes in China. Today, at the fourth China International Import Expo, Sanofi hosted the themed event "Sanofi Moments, D-Legends" and Toujeo^®First Anniversary Celebration of Market Launch. The event was remotely hosted by Professor Guo Lixin, President-Elect of the Chinese Diabetes Society under the Chinese Medical Association. Renowned diabetes experts in China and senior executives from Sanofi participated through a hybrid online-offline format, sharing insights on the diagnosis, treatment, and management of diabetes, and showcasing the latest advancements in innovative products and the digital chronic disease management ecosystem to the public.

“Savoring Moments, Crafting Legends” Thematic Event & Toujeo® 1st Anniversary Launch Celebration

Drug Introduction Provides a Novel Glucose-Lowering Option

Sanofi is one of the first companies in the world to manufacture insulin and has achieved multiple major breakthroughs in insulin research and development. Meanwhile, while continuing to provide high-quality medicines, Sanofi is continuously accelerating the introduction of innovative insulins to meet the unmet clinical needs of diabetic patients in China.

Last year, Sanofi's innovative ultra-long-acting basal insulin Toujeo^®(Insulin glargine U300) was officially launched in China for the treatment of adults with type 2 diabetes mellitus requiring insulin therapy. Compared with similar insulin therapies, Toujeo^®Reduces glycemic variability, lowers the risk of hypoglycemia, enables more stable and effective attainment of glycemic targets, and provides a more reassuring injectable therapy experience.

Professor Peng Yongde of the First People's Hospital Affiliated to Shanghai Jiao Tong University pointed out that: “Hypoglycemia, as the most common adverse reaction in insulin therapy, not only affects insulin dose titration but also increases the rate of treatment discontinuation, hindering patients from achieving glycemic targets. Toujeo^®The unique sustained-release mechanism, superior glucose-lowering efficacy, and dosing flexibility can meet the needs of diverse patients, enhance safety and adherence, and further improve the rate of achieving glycemic control targets.”

This September, with Toujeo^®On the First Anniversary of Approval, Sanofi's Fixed-Ratio Combination of Basal Insulin and GLP-1RA, SOLIQUA^®The New Drug Application (NDA) for (iGlarLixi) has been officially accepted by the National Medical Products Administration (NMPA). The Phase III clinical trial conducted by Sanofi in China has also been officially announced simultaneously,confirmedEfficacy and safety of iGlarLixi. Study results demonstrated that, compared with the basal insulin treatment group, patients receiving iGlarLixi achieved the predefined primary efficacy endpoint in reducing glycated hemoglobin (HbA1c). At 30 weeks of treatment, the mean HbA1c in the iGlarLixi group reached 6.7%, compared with 7.4% in the basal insulin group. The iGlarLixi group demonstrated superior postprandial glucose and body weight control compared with basal insulin, with a hypoglycemia incidence similar to that of the basal insulin group.

Prof. Dajin Zou, Tenth People's Hospital, Tongji Universitystated: "We are delighted to see that the clinical trial data fully confirm the efficacy and safety of iGlarLixi. Specifically, at week 30, the proportion of patients achieving the HbA1c target (HbA1c < 7%) in the iGlarLixi treatment group was 63%, compared with 30% in the basal insulin group. Additionally, iGlarLixi requires only once-daily administration and is associated with a low risk of hypoglycemia and weight gain. We greatly look forward to the market launch of this new drug, which will provide a novel glucose-lowering option for diabetic patients across China."

Digital Innovation Builds a Chronic Disease Management Ecosystem

China has a large diabetic population, with approximately 129.8 million patients.^[1]，ranking first globally. Currently, diabetes treatment in China faces numerous challenges, such as a low treatment target attainment rate, inadequate patient education, and severe challenges in complication prevention and control, all of which urgently need to be addressed. Sanofi is committed to integrating innovative medicines and comprehensive solutions that combine diagnosis and treatment, services, and data analytics into China's diabetes prevention and control initiatives, leading the wave of innovation in diabetes management.

As early as 2014, Sanofi launched the "TRIO" project to explore the application of digital technologies in empowering diabetes management. By connecting physicians, nurses, and patients, the initiative employs a data-driven and AI-powered management model to deliver phased, stratified, and round-the-clock personalized interventions, helping patients achieve optimal therapeutic outcomes. Over the past eight years, the project has expanded to more than 550 hospitals across China, cumulatively serving over 700,000 patients with diabetes.

Prof. Yaoming Xue, Nanfang Hospital, Southern Medical Universitystated: "The process of diabetes management is complex and prolonged, encompassing everything from screening and in-hospital diagnosis to the out-of-hospital implementation of treatment plans. The 'Smart Care Trio' project extends in-hospital treatment to out-of-hospital settings, enabling the healthcare team to provide continuous monitoring and care for diabetic patients throughout the entire journey. By promptly adjusting treatment regimens according to individual patient conditions, it improves target attainment rates and patient adherence, thereby achieving optimal glycemic management and ultimately enhancing patients' quality of life."

Ms. Qiu Youping, General Manager, Diabetes Business Unit, Sanofi Chinastated: “The digital diabetes management model has proven highly effective in helping more patients with diabetes achieve their treatment targets, while simultaneously enabling Sanofi to accumulate extensive chronic disease management expertise. Moving forward, Sanofi will continue to lead in the diabetes sector by accelerating the introduction of innovative products into China, steadfastly advancing digital transformation, and actively exploring innovative, internet-based chronic disease management solutions. Our goal is to bring healthy living to a broad population of diabetes patients across China, ultimately realizing our vision of reversing the growing prevalence of chronic diseases by 2030.”

^*SOLIQUA^®(iGlarLixi)Not yet approved in China

^[1] Yongze Li, Di Teng, Xiaoguang Shi, et al., Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ, 2020. 369: p. m997.

About Sanofi China

Sanofi is a globally leading biopharmaceutical company dedicated to human health. As one of the first multinational enterprises to enter China following the Reform and Opening-up, Sanofi established an office in China in 1982. Sanofi China’s diversified business covers pharmaceuticals, human vaccines, and consumer healthcare. In China, Sanofi operates 12 offices, 3 manufacturing sites, 4 R&D centers, and 1 digital innovation center. Sanofi is committed to accelerating the introduction of innovative medicines and vaccines to China and leading digital innovation, thereby meeting the healthcare needs of the broadest population across China.

For more information, please visitwww.sanofi.cn, or follow the "Sanofi China" WeChat Official Account and "Sanofi" LinkedIn account.

About Sanofi

Sanofi is dedicated to helping people overcome health challenges. We are a global biopharmaceutical company focused on human health. We prevent diseases through vaccines and provide innovative treatments to alleviate pain and suffering. We support the few living with rare diseases and stand by the millions of patients managing chronic conditions over the long term.

Sanofi has over 100,000 employees across more than 100 countries, dedicated to transforming scientific innovation into healthcare solutions.

Sanofi, Empowering Life

Sanofi Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements are not statements of historical facts. These statements include forecasts and estimates along with their underlying assumptions, statements regarding the Company’s future plans, objectives, and intentions, expectations regarding future financial condition, events, operations, services, product development, and potential, as well as statements concerning future performance. Forward-looking statements can generally be identified by the use of words such as “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that such forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, which could cause actual results and developments to differ materially from those expressed, implied, or forecasted in the forward-looking information and statements. These risks and uncertainties include, but are not limited to, uncertainties inherent in research and development, future clinical data and analyses, including post-marketing data and analyses, decisions by regulatory authorities, such as the U.S. Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, medical device, or biological product filing for a candidate product, as well as decisions by these authorities concerning product labeling and other matters that could affect the availability and commercial potential of such candidate products, the possibility that approved candidate products may not achieve commercial success, the approval and commercial success of future alternative therapies, the Group’s ability to benefit from external growth opportunities and complete related transactions and/or obtain regulatory approvals, risks related to intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, volatile economic and market conditions, the impact of global disruptions including global pandemics, trends in exchange rates and prevailing interest rates, cost-control policies and their outcomes, the average number of shares outstanding, and other factors discussed or identified in Sanofi’s public filings with the U.S. Securities and Exchange Commission (SEC) and the Autorité des Marchés Financiers (AMF), including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s Annual Report on Form 20-F for the year ended December 31, 2020. Except as required by applicable law, Sanofi assumes no obligation to update or revise any forward-looking information or statements.